Michael King
Stock Analyst at EF Hutton
(1.02)
# 3,501
Out of 4,829 analysts
117
Total ratings
34.15%
Success rate
-16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $5.49 | +11,739.71% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $1.28 | +92,025.00% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.98 | +176.38% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.63 | +1,863.19% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $4.52 | +1,415.49% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $9.50 | +2,005.26% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.80 | +937.76% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $527.78 | +63.33% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $36.17 | -33.65% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $2.91 | +5,604.47% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $8.33 | +404.20% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $251.15 | +21.04% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $8.12 | +1,328.57% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.82 | +465.93% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $30.67 | -21.75% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.78 | +101,862.78% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $19.62 | +134.45% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $27.32 | +251.39% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.71 | +4,970.42% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.34 | +3,398.54% | 1 | Dec 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $4.81 | +544.49% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $549.27 | -93.45% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $5.49
Upside: +11,739.71%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $1.28
Upside: +92,025.00%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.98
Upside: +176.38%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.63
Upside: +1,863.19%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $4.52
Upside: +1,415.49%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $9.50
Upside: +2,005.26%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.80
Upside: +937.76%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $527.78
Upside: +63.33%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $36.17
Upside: -33.65%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $2.91
Upside: +5,604.47%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $8.33
Upside: +404.20%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $251.15
Upside: +21.04%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $8.12
Upside: +1,328.57%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $1.82
Upside: +465.93%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $30.67
Upside: -21.75%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.78
Upside: +101,862.78%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $19.62
Upside: +134.45%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $27.32
Upside: +251.39%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.71
Upside: +4,970.42%
Dec 23, 2021
Initiates: Buy
Price Target: $12
Current: $0.34
Upside: +3,398.54%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $4.81
Upside: +544.49%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $549.27
Upside: -93.45%